Carcinoma  >>  Mekinist (trametinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mekinist (trametinib) / Novartis, BeiGene
NCT01362296: An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Checkmark WCLC 2013
Oct 2013 - Oct 2013: WCLC 2013
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
134
US, Europe, RoW
GSK1120212, docetaxel
GlaxoSmithKline
Lung Cancer, Non-Small Cell
09/12
09/13
NCT01553851: GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

Completed
2
20
US
GSK1120212, Trametinib, Mekinist
Washington University School of Medicine, National Comprehensive Cancer Network
Neoplasms, Oral, Mouth Neoplasms
06/15
12/15
SWOG-S1310, NCT02042443: Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery

Completed
2
53
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
National Cancer Institute (NCI)
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma, Hilar Cholangiocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Childhood Liver Cancer, Recurrent Extrahepatic Bile Duct Carcinoma, Recurrent Gallbladder Carcinoma, Stage II Gallbladder Cancer, Stage III Childhood Hepatocellular Carcinoma, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Childhood Hepatocellular Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma
01/17
04/17
NCT02672358: Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Withdrawn
2
0
NA
Dabrafenib, Trametinib
Novartis Pharmaceuticals
Non-Small-Cell Lung Cancer
09/19
12/20
NCT02580708: Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Terminated
1/2
7
US
Rociletinib, CO-1686, Trametinib, Mekinist
Clovis Oncology, Inc., Novartis Pharmaceuticals
Non-small Cell Lung Cancer
05/16
06/16

Download Options